



cfc

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent No. 7,087,583) Serial No. 09/813,824
Inventor(s): Bert VOGELSTEIN et al.) Filed: March 22, 2001
Issue Date: August 8, 2006) Attorney Docket No. 001107.00112
For: SEQUENCE SPECIFIC DNA BINDING BY P53

REQUEST FOR CERTIFICATE OF CORRECTION

U.S. Patent and Trademark Office
Customer Service Window
Randolph Building, Mail Stop: Certificate of Correction Branch
401 Dulany Street
Alexandria, VA 22314

**Certificate
DEC 12 2006
of Correction**

Sir:

Pursuant to 35 U.S.C. § 254 and 37 C.F.R. § 1.322, this is a request for the issuance of a Certificate of Correction in the above-identified patent. Two (2) copies of PTO Form 1050 are appended. The complete Certificate of Correction involves 1 page.

The mistake identified in the appended Form occurred through no fault of the Applicants, as clearly disclosed by the records of the application, which matured into this patent. Enclosed for your convenience is a copy of the amended claim.

Issuance of the Certificate of Correction containing the correction is respectfully requested. Since this change is necessitated through no fault of the Applicants, no fee is believed to be associated with this request. Nonetheless, should the Patent and Trademark Office determine that a fee is required, please charge our Deposit Account No. 19-0733.

Respectfully submitted,

BANNER & WITCOFF, LTD.

Dated: December 8, 2006

1001 G Street, N.W. (11th Fl.)
Washington, D.C. 20001
(202) 824-3000

By: Sarah A. Kagan

Sarah A. Kagan
Registration No. 32,141

DEC 13 2006

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO.: 7,087,583

DATED: November 22, 2006

INVENTOR(S): Bert VOGELSTEIN, Kenneth W. KINZLER, Michael I. SHERMAN

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In Claim 6, Column 43, Line 50:

Please delete "of p53 a gene adjacent" and insert -- of a gene adjacent--

Mailing Address of Sender:

Banner & Witcoff, Ltd.
11th Floor
1001 G Street, N.W.
Washington, DC 20001-4597

FORM PTO 1050 (Rev.2-93)

U.S. PAT. NO 7,087,583

No. of add'l copies
@ \$0.50 per page

☐

DEC 13 2006

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO.: 7,087,583

DATED: November 22, 2006

INVENTOR(S): Bert VOGELSTEIN, Kenneth W. KINZLER, Michael I. SHERMAN

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In Claim 6, Column 43, Line 50:

Please delete "of p53 a gene adjacent" and insert -- of a gene adjacent--

Mailing Address of Sender:

Banner & Witcoff, Ltd.
11th Floor
1001 G Street, N.W.
Washington, DC 20001-4597

FORM PTO 1050 (Rev.2-93)

U.S. PAT. NO 7,087,583

No. of add'l copies
@ \$0.50 per page

☐

DEC 13 2006

providing to a cell a compound, which comprises a single-stranded, linear or circular, oligonucleotide or oligonucleotide containing nucleotide analogs, wherein the oligonucleotide or oligonucleotide containing nucleotide analogs comprises at least two of the monomer sequence TGCCT or the complement thereof, whereby growth of the cell is suppressed.

43. (Currently amended) A method of activating transcription of ~~p53-regulated genes~~ a gene in a cell, comprising the steps of:

providing to a cell a compound which comprises a single-stranded, linear or circular, oligonucleotide or oligonucleotide containing nucleotide analogs, wherein said compound comprises the monomer sequence RRRCWWGYYY (SEQ ID NO: 3) or the complement thereof, wherein said compound is able to complex specifically with a p53-specific binding site, ~~whereby transcription of p53-regulated genes a gene adjacent to the~~
p53 specific binding site is activated in the cell.

44. (Cancelled)

45. (Cancelled)

46. (Cancelled)

47. (Currently amended) A method of activating transcription of ~~p53-regulated genes~~ a gene in a cell, comprising the steps of:

providing to a cell a compound, which comprises a single-stranded, linear or circular, oligonucleotide or oligonucleotide containing nucleotide analogs, wherein the oligonucleotide or oligonucleotide containing nucleotide analogs comprises at least two of the monomer sequence TGCCT or the complement thereof, whereby transcription of